{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:00:40Z","timestamp":1792184440158,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Recently, the International Consensus Classification (ICC) and the 5\n                    <jats:sup>th<\/jats:sup>\n                    edition of the World Health Organization classification (WHO2022) introduced diagnostically similar yet distinct approaches, which has resulted in practical confusion. This review compares these classification systems for acute myeloid leukemia (AML), building up on the revised 4th edition of WHO (WHO2016). Both classifications retain recurrent genetic abnormalities as a primary consideration. However, they differ in terms of blast threshold. The ICC mandates a minimum of 10% blasts in the bone marrow or peripheral blood, whereas the WHO2022 does not specify a blast cut-off. AML with\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    requires\u2009&gt;\u200920% blast count in both classifications. In WHO2022, AML with\n                    <jats:italic>CEBPA<\/jats:italic>\n                    mutation requires\u2009&gt;\u200920% blasts.\n                    <jats:italic>TP53<\/jats:italic>\n                    mutation, a new entity is exclusive to ICC, diagnosed with\u2009&gt;\u200920% blasts and variant allele frequency\u2009&gt;\u200910%. AML with myelodysplasia-related changes is defined by cytogenetic or gene mutation-based criteria, not morphological dysplasia. Eight genes were common to both groups:\n                    <jats:italic>ASXL1<\/jats:italic>\n                    ,\n                    <jats:italic>BCOR<\/jats:italic>\n                    ,\n                    <jats:italic>EZH2<\/jats:italic>\n                    ,\n                    <jats:italic>SF3B1<\/jats:italic>\n                    ,\n                    <jats:italic>SRSF2<\/jats:italic>\n                    ,\n                    <jats:italic>STAG2<\/jats:italic>\n                    ,\n                    <jats:italic>U2AF1<\/jats:italic>\n                    , and\n                    <jats:italic>ZRSR2<\/jats:italic>\n                    . An additional gene,\n                    <jats:italic>RUNX1<\/jats:italic>\n                    , was included in the ICC classification. AML cases defined by differentiation (WHO2022) and AML not otherwise specified (ICC) are categorized as lacking specific defining genetic abnormalities, WHO2022 labels this as a myeloid neoplasm post cytotoxic therapy (MN-pCT), described as an appendix after specific diagnosis. Similarly, in ICC, it can be described as \u201ctherapy-related\u201d, without a separate AML category.\n                  <\/jats:p>","DOI":"10.1007\/s44313-024-00016-8","type":"journal-article","created":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T19:02:31Z","timestamp":1713121351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["What is new in acute myeloid leukemia classification?"],"prefix":"10.1007","volume":"59","author":[{"given":"Hee Sue","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"101518","DOI":"10.1016\/j.beha.2023.101518","volume":"36","author":"FR Appelbaum","year":"2023","unstructured":"Appelbaum FR. WHO, what, when, where, and why: new classification systems for acute myeloid leukemia and their impact on clinical practice. Best Pract Res Clin Haematol. 2023;36:101518.","journal-title":"Best Pract Res Clin Haematol"},{"key":"16_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ajh.26812","volume":"98","author":"B Falini","year":"2023","unstructured":"Falini B, Martelli MP. Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia. Am J Hematol. 2023;98:481\u201392.","journal-title":"Am J Hematol"},{"key":"16_CR3","doi-asserted-by":"publisher","first-page":"e767","DOI":"10.1016\/S2352-3026(23)00159-X","volume":"10","author":"RM Shallis","year":"2023","unstructured":"Shallis RM, Daver N, Altman JK, et al. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. Lancet Haematol. 2023;10:e767\u201376.","journal-title":"Lancet Haematol"},{"key":"16_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00428-022-03430-4","volume":"482","author":"OK Weinberg","year":"2023","unstructured":"Weinberg OK, Porwit A, Orazi A, et al. The International Consensus Classification of acute myeloid leukemia. Virchows Arch. 2023;482:27\u201337.","journal-title":"Virchows Arch"},{"key":"16_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"16_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","volume":"33","author":"JM Bennett","year":"1976","unstructured":"Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451\u20138.","journal-title":"Br J Haematol"},{"key":"16_CR7","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. 3rd ed. Lyon, France: IARC Press; 2001."},{"key":"16_CR8","unstructured":"Swerdlow SH, Campo E, Harris NL, et al editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008."},{"key":"16_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"16_CR10","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"16_CR11","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood.2019004226","volume":"136","author":"B Falini","year":"2020","unstructured":"Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood. 2020;136:1707\u201321.","journal-title":"Blood"},{"key":"16_CR12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.5045\/br.2020.S001","volume":"55","author":"SM Hwang","year":"2020","unstructured":"Hwang SM. Classification of acute myeloid leukemia. Blood Res. 2020;55:S1\u20134.","journal-title":"Blood Res"},{"key":"16_CR13","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood-2010-08-299990","volume":"117","author":"B Falini","year":"2011","unstructured":"Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117:1109\u201320.","journal-title":"Blood"},{"key":"16_CR14","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","volume":"3","author":"G Montalban-Bravo","year":"2019","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, et al. NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019;3:922\u201333.","journal-title":"Blood Adv"},{"key":"16_CR15","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.3390\/ijms21238975","volume":"21","author":"F Forghieri","year":"2020","unstructured":"Forghieri F, Nasillo V, Paolini A, et al. NPM1-mutated myeloid neoplasms with< 20% blasts: a really distinct clinico-pathologic entity? International J Mol Sci. 2020;21:8975.","journal-title":"International J Mol Sci"},{"key":"16_CR16","doi-asserted-by":"publisher","first-page":"806137","DOI":"10.3389\/fonc.2022.806137","volume":"12","author":"L Su","year":"2022","unstructured":"Su L, Shi Y-Y, Liu Z-Y, Gao S-J. Acute myeloid leukemia with CEBPA mutations: current progress and future directions. Front Oncol. 2022;12:806137.","journal-title":"Front Oncol"},{"key":"16_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/gcc.10185","volume":"37","author":"J Snaddon","year":"2003","unstructured":"Snaddon J, Smith ML, Neat M, et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer. 2003;37:72\u20138.","journal-title":"Genes Chromosomes Cancer"},{"key":"16_CR18","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26:1549\u201356.","journal-title":"Nat Med"},{"key":"16_CR19","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.3324\/haematol.2022.281653","volume":"108","author":"EJ Bertrums","year":"2023","unstructured":"Bertrums EJ, Smith JL, Harmon L, et al. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023;108:2044.","journal-title":"Haematologica"},{"key":"16_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/ajcp\/aqab172","volume":"157","author":"Y Gao","year":"2022","unstructured":"Gao Y, Jia M, Mao Y, et al. Distinct mutation landscapes between acute myeloid leukemia with myelodysplasia-related changes and de novo acute myeloid leukemia. Am J Clin Pathol. 2022;157:691\u2013700.","journal-title":"Am J Clin Pathol"},{"key":"16_CR21","doi-asserted-by":"publisher","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","volume":"13","author":"Y Tazi","year":"2022","unstructured":"Tazi Y, Arango-Ossa JE, Zhou Y, et al. Unified classification and risk-stratification in acute myeloid leukemia. Nat Commun. 2022;13:4622.","journal-title":"Nat Commun"},{"key":"16_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-01010-w","volume":"23","author":"TB Alexander","year":"2021","unstructured":"Alexander TB, Orgel E. Mixed phenotype acute leukemia: current approaches to diagnosis and treatment. Curr Oncol Rep. 2021;23:1\u201310.","journal-title":"Curr Oncol Rep"},{"key":"16_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"16_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"16_CR25","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/bjh.17336","volume":"192","author":"S Kayser","year":"2021","unstructured":"Kayser S, Hills RK, Langova R, et al. Characteristics and outcome of patients with acute myeloid leukaemia and t (8; 16)(p11; p13): results from an International Collaborative Study. Br J Haematol. 2021;192:832\u201342.","journal-title":"Br J Haematol"},{"key":"16_CR26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.2019003701","volume":"136","author":"S Ottema","year":"2020","unstructured":"Ottema S, Mulet-Lazaro R, Beverloo HB, et al. Atypical 3q26\/MECOM rearrangements genocopy inv (3)\/t (3; 3) in acute myeloid leukemia. Blood. 2020;136:224\u201334.","journal-title":"Blood"},{"key":"16_CR27","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1200\/JCO.21.00067","volume":"39","author":"NJ Short","year":"2021","unstructured":"Short NJ, Tallman MS, Pollyea DA, Ravandi F, Kantarjian H. Optimizing risk stratification in acute myeloid leukemia: dynamic models for a dynamic therapeutic landscape. J Clin Oncol. 2021;39:2535.","journal-title":"J Clin Oncol"},{"issue":"S1","key":"16_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5045\/br.2022.2022017","volume":"57","author":"J-S Ahn","year":"2022","unstructured":"Ahn J-S, Kim H-J. FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs. Blood Res. 2022;57(S1):32\u20133.","journal-title":"Blood Res"},{"issue":"3","key":"16_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5045\/br.2023.2023136","volume":"58","author":"D-S Kim","year":"2023","unstructured":"Kim D-S, Byun J-M, Shin D-Y, et al. Concomitant ruxolitinib with cytarabine-bassed induction chemotherapy in secondary acute meyloid leukemia evolving from myeloproliferative neoplasm. Blood Res. 2023;58(3):155\u20137.","journal-title":"Blood Res"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-024-00016-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-024-00016-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-024-00016-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T19:07:23Z","timestamp":1713121643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-024-00016-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s44313-024-00016-8","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"29 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review did not require approval from the relevant institutional review board or ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}